About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

iShares U.S. Healthcare ETF (NY:IYH)

60.53 +0.11 (+0.18%)
Streaming Delayed Price Updated: 11:36 AM EDT, May 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about iShares U.S. Healthcare ETF

< Previous 1 2 3 Next >
News headline image
Novavax Swings To Profit In Q4 Fueled By Nuvaxovid-Linked Revenue ↗
The company generated $147 million in revenue during Q4, a 67% year-on-year (YoY) increase. Earnings per share (EPS) for the quarter were $0.11. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
PRCT Stock Tumbles Pre-Market: BofA Questions Earnings Visibility, Cuts Target To $20 ↗
Bank of America reduced its rating on PROCEPT BioRobotics to ‘Underperform’ from ‘Neutral’. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Why Did IXHL Stock Tank Over 32% Today? ↗
The company’s board approved a 1-for-30 reverse stock split, effective on February 26. 
Via Stocktwits
News headline image
Why Did GERN Stock Tumble 10% Pre-Market Today? ↗
Total revenue reached $48 million for the fourth-quarter with a loss per share (EPS) of $0.05, with both metrics coming in below street estimates. 
Via Stocktwits
Topics Artificial Intelligence
Janux Stock Is Rising Pre-Market After A New Oncology Deal With Bristol Myers Squibb ↗
Via Stocktwits
FDA To Ease Review Process For Life-Saving Gene-Editing Therapies: Report ↗
Via Stocktwits
Trump Says He's 'Happy To Work' With Democrats On 'Failed' Healthcare Policies, But Calls To End Government Shutdown ↗
Via Stocktwits
Topics Government
News headline image
Why Did Larimar Therapeutics’ Stock Surge Over 30% Pre-Market Today? ↗
The FDA has granted Breakthrough Therapy Designation to Larimar’s frataxin protein replacement therapy, nomlabofusp. 
Via Stocktwits
News headline image
VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership ↗
Raymond James analyst Sean McCutcheon upgraded the stock to ‘Strong Buy’ from ‘Outperform’ and lifted his price target to $19 from $12. 
Via Stocktwits
News headline image
Why Did IOVA Stock Gain Pre-Market Today? ↗
The company announced encouraging early results from a pilot study evaluating its tumor-infiltrating lymphocyte therapy, lifileucel and reported strong fourth-quarter earnings. 
Via Stocktwits
News headline image
Merck Is Reportedly Splitting Its Pharma Division As Keytruda Patent Nears 2028 Expiry ↗
According to a Wall Street Journal report, the drugmaker said it will reorganize its human health segment into two separate units in an effort to better position its portfolio for the years ahead. 
Via Stocktwits
Topics Intellectual Property
Retail Traders Evenly Split About Government Shutdown Odds: Strategists Weigh In On Whether Jobs Report Would Be Delayed Amid Looming Risk ↗
Via Stocktwits
News headline image
Why Is GRAL Stock Down Today? Analysts Lower Targets After UK Trial Setback But Call Selloff Overdone ↗
Baird analyst Catherine Ramsey Schulte slashed the price target on Grail to $82 from $113 while reiterating an ‘Outperform’ rating. 
Via Stocktwits
News headline image
Why Did IMUX Stock Surge 33% Pre-Market Today? ↗
Immunic announced a private placement of up to $400 million to support its clinical studies and other operational needs. 
Via Stocktwits
News headline image
Why Did Healthcare Triangle Stock Plummet 20% Today? ↗
The technology firm announced that it will implement a 1-for-60 reverse stock split of its common shares effective at 12:01 a.m. Eastern Time on February 10. 
Via Stocktwits
News headline image
Why Did Corcept Therapeutics Stock Surge Over 14% Today? ↗
In the ROSELLA trial, patients receiving relacorilant with nab-paclitaxel saw their risk of death drop by about 35% compared with those given the chemotherapy alone. 
Via Stocktwits
News headline image
Monster Beverage, UnitedHealth, Thermo Fisher Scientific And More: CNBC's 'Final Trades' ↗
Today's "Final Trades" segment focused on UnitedHealth, Thermo Fisher Scientific, iShares U.S. Healthcare ETF and Monster Beverage. 
Via Benzinga
Topics ETFs
News headline image
Why Is Co-Diagnostics Stock Sinking Tuesday? ↗
Co-Diagnostics (CODX) stock falls over 50% as they announced a $7 million offering and Saudi joint venture, causing concerns about dilution. 
Via Benzinga
News headline image
Wellgistics And DataVault Team Up To Transform Prescription Tracking ↗
DataVault AI and Wellgistics Health are collaborating to bring blockchain technology to the US prescription drug market. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Premier Set For Private Ownership, Eyes Growth Push ↗
Premier Inc. to be acquired by Patient Square Capital at $28.25 per share, offering shareholders a 23.8% premium. 
Via Benzinga
News headline image
As the Market Rotates, This Healthcare ETF Is Leading the Way ↗
Health care saw some of the worst losses this year. But as the calendar turned to August, it's been leading the market higher. This ETF provides exposure. 
Via MarketBeat
Topics ETFs
News headline image
Brace For Higher Healthcare Premiums In 2026 As Insurers Blame Trump's Tariffs In Filings To Regulators: Report ↗
Health insurance companies have raised concerns that tariffs could lead to higher premiums for enrollees in the individual and small group markets next year. 
Via Benzinga
Topics Government World Trade
News headline image
Omada Health Prices $150M IPO In-Line With Estimated Range ↗
Omada Health (OMDA) priced its IPO at $19 per share, midpoint of the previously estimated price range of $18.00 and $20.00 per share 
Via Stocktwits
Topics Initial Public Offering
News headline image
Guardian Pharmacy Strengthens US Footprint With New Seattle-Area Acquisition ↗
Guardian Pharmacy Services acquires Mercury Pharmacy Services in Washington, expanding its presence in the Pacific Northwest and meeting growing demand for LTC support. 
Via Benzinga
News headline image
Tariffs Bite Dan Loeb's Portfolio: Thermo Fisher Hit Hard, Discover Shines ↗
Year to date, Thermo Fisher fell about 21.03%, both underperforming the iShares U.S. Healthcare ETF, which declined about 2.36%. 
Via Benzinga
Topics ETFs
News headline image
Healthcare Sector Trying To Bounce Back ↗
I often discuss highly rated stocks that are part of highly rated sectors. Thus, this time is a departure from the norm. Let's dive into the data for the healthcare sector. 
Via Talk Markets
Topics ETFs Stocks / Equities
News headline image
Is It Time To Shift Focus To Beaten-Down Healthcare Stocks As Volatility Soars? ↗
Healthcare performed terribly in 2023 and 2024, falling while the market was soaring. Year-to-date, the sector has outperformed. Is it time to focus on the stocks and ETFs of this low-Beta sector as... 
Via Talk Markets
Topics ETFs Stocks / Equities
News headline image
Dan Loeb Adjusts Healthcare Holdings: Danaher Stake Trimmed As Thermo Fisher Gains Favor ↗
Loeb's Third Point LLC restructured their portfolio in last quarter of 2024. They decreased stake in Danaher Corp. and acquired stake in Thermo Fisher. 
Via Benzinga
News headline image
NIH Funding Cuts To Spook Healthcare Stocks? RFK Jr's Confirmation At HHS Sparks Concerns Over Research Dollars, 'Causing Uncertainty,' Says Analyst ↗
Robert F. Kennedy Jr.'s appointment as Secretary of Health and Human Services has sparked concerns over funding for the NIH. 
Via Benzinga
News headline image
Spotify, Vertiv Holdings And More: CNBC's 'Final Trades' ↗
Joseph M. Terranova picked Spotify Technology, which reported better-than-expected fiscal fourth-quarter 2024 financial sales. 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.